Research desk · GLAXF · NYSE

SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.

GSK plc · Pharmaceutical Preparations

GSK plc financial statements, chart, and peer compare from SEC filings.

GSK plc (GLAXF) discovers, develops, or markets pharmaceutical products.

Market cap
$110.46B
P/E
—
Op. margin
24.28%
Profit margin
19.25%
FCF margin
19.57%
ROE
39.41%

Related Health Care stocks: BMY stock financials · REGN stock financials · ABBV stock financials · AMGN stock financials · MRK stock financials

See Health Care moving on the anomaly desk

misprise.com
Watch / incomplete (<60) FY2025 Updated October 19, 2026 1:41 am ← Screener
Primary research · 02

GLAXF financial statements

Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.

Primary research · 03

GLAXF stock peer compare

Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.

Focus chart

Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.

Supporting · 04

GLAXF stock peer headlines

Yahoo Finance RSS for GLAXF and the names in Compare.

Ticker Date Headline
Loading headlines…
Supporting · 05

GLAXF stock price chart

Overlays follow the Compare table.

Chart loads when you scroll here
Supporting · 06

GLAXF stock — research snapshot

Screen strengths and watchouts for GLAXF stock from the latest Misprise snapshot.

Strengths

  • ROA 10.3% — strong returns on assets.
  • ROE 39.4% — efficient equity returns.
  • Operating margin 24.3% — solid operating leverage.
  • Profit margin 19.3% — durable bottom-line quality.
  • FCF margin 19.6% — cash conversion looks healthy.

Watchouts

  • EPS CAGR negative — earnings trajectory is soft.
  • Current ratio 0.82 — near-term liquidity is tight.
  • Rev CAGR 5Y 6.1%
  • Rev CAGR 3Y 3.7%
  • EPS CAGR 5Y -0.5%
  • EPS CAGR 3Y -27.6%
  • FCF CAGR 5Y -3.0%
  • FCF CAGR 3Y 0.7%
Supporting · 07

GLAXF stock FAQs

Short answers for GLAXF stock — statements, sector, and how this page is meant to be used.

What is GLAXF stock?

GSK plc (GLAXF) discovers, develops, or markets pharmaceutical products. GLAXF stock sits in Health Care (Pharmaceutical Preparations), listed on NYSE.

Where can I find GSK plc financial statements?

GSK plc financial statements — income statement, balance sheet, and cash flow — are on this GLAXF stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.

What happened to GLAXF stock?

This page is a research snapshot of GSK plc (GLAXF) from the latest SEC filings in the Misprise database as of FY2025. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.

Does this page show the GLAXF stock price?

The live chart on this GLAXF stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.

What sector is GLAXF stock in?

GSK plc is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on NYSE. This page is a research snapshot, not a full company profile.

How do I read GLAXF financial statements?

Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.

Where does the GLAXF statement data come from?

Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.

Where can I find the GLAXF income statement, balance sheet, and cash flow?

On this GLAXF stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.

What is the Misprise Score for GLAXF stock?

GLAXF stock currently scores 45/100 (Watch / incomplete (<60)). GSK plc scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.

How is the GLAXF comparison winner decided?

Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.

What is the Anomaly Score on this GLAXF page?

Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.

What does the green grant dot mean on GLAXF stock?

A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.

Is GLAXF stock a buy?

No recommendation either way. This GLAXF stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell GSK plc.